Literature DB >> 21325621

Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor.

Amol Suryawanshi1, Sachin Mulik, Shalini Sharma, Pradeep B J Reddy, Sharvan Sehrawat, Barry T Rouse.   

Abstract

The normal cornea is transparent, which is essential for normal vision, and although the angiogenic factor vascular endothelial growth factor A (VEGF-A) is present in the cornea, its angiogenic activity is impeded by being bound to a soluble form of the VEGF receptor-1 (sVR-1). This report investigates the effect on the balance between VEGF-A and sVR-1 that occurs after ocular infection with HSV, which causes prominent neovascularization, an essential step in the pathogenesis of the vision-impairing lesion, stromal keratitis. We demonstrate that HSV-1 infection causes increased production of VEGF-A but reduces sVR-1 levels, resulting in an imbalance of VEGF-A and sVR-1 levels in ocular tissues. Moreover, the sVR-1 protein made was degraded by the metalloproteinase (MMP) enzymes MMP-2, -7, and -9 produced by infiltrating inflammatory cells that were principally neutrophils. Inhibition of neutrophils, inhibition of sVR-1 breakdown with the MMP inhibitor marimastat, and the provision of exogenous recombinant sVR-1 protein all resulted in reduced angiogenesis. Our results make the novel observation that ocular neovascularization resulting from HSV infection involves a change in the balance between VEGF-A and its soluble inhibitory receptor. Future therapies aimed to increase the production and activity of sVR-1 protein could benefit the management of stromal keratitis, an important cause of human blindness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325621      PMCID: PMC3892272          DOI: 10.4049/jimmunol.1003239

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.

Authors:  Hiroaki Nozawa; Christopher Chiu; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-04       Impact factor: 11.205

2.  Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection.

Authors:  Partha Sarathi Biswas; Kaustuv Banerjee; Paul R Kinchington; Barry T Rouse
Journal:  Exp Eye Res       Date:  2005-07-11       Impact factor: 3.467

3.  Corneal avascularity is due to soluble VEGF receptor-1.

Authors:  Balamurali K Ambati; Miho Nozaki; Nirbhai Singh; Atsunobu Takeda; Pooja D Jani; Tushar Suthar; Romulo J C Albuquerque; Elizabeth Richter; Eiji Sakurai; Michael T Newcomb; Mark E Kleinman; Ruth B Caldwell; Qing Lin; Yuichiro Ogura; Angela Orecchia; Don A Samuelson; Dalen W Agnew; Judy St Leger; W Richard Green; Parameshwar J Mahasreshti; David T Curiel; Donna Kwan; Helene Marsh; Sakae Ikeda; Lucy J Leiper; J Martin Collinson; Sasha Bogdanovich; Tejvir S Khurana; Masabumi Shibuya; Megan E Baldwin; Napoleone Ferrara; Hans-Peter Gerber; Sandro De Falco; Jassir Witta; Judit Z Baffi; Brian J Raisler; Jayakrishna Ambati
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects.

Authors:  Bumseok Kim; Susmit Suvas; Pranita P Sarangi; Sujin Lee; Ralph A Reisfeld; Barry T Rouse
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

5.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.

Authors:  Bumseok Kim; Qingquan Tang; Partha S Biswas; Jun Xu; Raymond M Schiffelers; Frank Y Xie; Aslam M Ansari; Puthupparampil V Scaria; Martin C Woodle; Patrick Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

7.  Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.

Authors:  Veronica C Ardi; Tatyana A Kupriyanova; Elena I Deryugina; James P Quigley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

Review 8.  VEGF-A and the induction of pathological angiogenesis.

Authors:  Janice A Nagy; Ann M Dvorak; Harold F Dvorak
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

9.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.

Authors:  Sunyoung Lee; Shahla M Jilani; Ganka V Nikolova; Darren Carpizo; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2005-05-23       Impact factor: 10.539

10.  Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.

Authors:  S A Watson; T M Morris; H M Collins; L J Bawden; K Hawkins; E A Bone
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  42 in total

1.  Role of miR-155 in the pathogenesis of herpetic stromal keratitis.

Authors:  Siddheshvar Bhela; Sachin Mulik; Fernanda Gimenez; Pradeep B J Reddy; Raphael L Richardson; Siva Karthik Varanasi; Ujjaldeep Jaggi; John Xu; Patrick Y Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2015-02-18       Impact factor: 4.307

2.  IL-17A differentially regulates corneal vascular endothelial growth factor (VEGF)-A and soluble VEGF receptor 1 expression and promotes corneal angiogenesis after herpes simplex virus infection.

Authors:  Amol Suryawanshi; Tamara Veiga-Parga; Pradeep B J Reddy; Naveen K Rajasagi; Barry T Rouse
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

3.  The inflammasome NLRP3 plays a protective role against a viral immunopathological lesion.

Authors:  Fernanda Gimenez; Siddheshvar Bhela; Pranay Dogra; Lorena Harvey; Siva Karthik Varanasi; Ujjaldeep Jaggi; Barry T Rouse
Journal:  J Leukoc Biol       Date:  2015-10-29       Impact factor: 4.962

4.  Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis.

Authors:  Sachin Mulik; Shalini Sharma; Amol Suryawanshi; Tamara Veiga-Parga; Pradeep B J Reddy; Naveen K Rajasagi; Barry T Rouse
Journal:  J Immunol       Date:  2011-05-13       Impact factor: 5.422

Review 5.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

6.  Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology.

Authors:  Amol Suryawanshi; Tamara Veiga-Parga; Naveen K Rajasagi; Pradeep Babu Jagdeesh Reddy; Sharvan Sehrawat; Shalini Sharma; Barry T Rouse
Journal:  J Immunol       Date:  2011-07-15       Impact factor: 5.422

Review 7.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

8.  Production of the Cytokine VEGF-A by CD4+ T and Myeloid Cells Disrupts the Corneal Nerve Landscape and Promotes Herpes Stromal Keratitis.

Authors:  Hongmin Yun; Michael B Yee; Kira L Lathrop; Paul R Kinchington; Robert L Hendricks; Anthony J St Leger
Journal:  Immunity       Date:  2020-11-17       Impact factor: 31.745

9.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Authors:  Gilbert G Jose; Inna V Larsen; Joshua Gauger; Erica Carballo; Rebecca Stern; Rachel Brummel; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

10.  Galectin-1-mediated suppression of Pseudomonas aeruginosa-induced corneal immunopathology.

Authors:  Amol Suryawanshi; Zhiyi Cao; Thananya Thitiprasert; Tanveer S Zaidi; Noorjahan Panjwani
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.